ERBB2 and neoplasm: Three PDACs showing four HER2 copy number at NGS analysis were negative for HER2 amplification, while the remaining PDAC revealed 20% of cells with HER2 amplification and was classified as a heterogeneous tumor for HER2 amplification (see Table 2).